Q3 2025 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2025-11-14 · accession 0001104659-25-112427
$1.11B
Reported value
17
Positions
2025-09-30
Period end
The Brief · Fairmount Funds Management LLC · Q3 2025
AI · grounded in 13F
Fairmount Funds Management LLC established a new position in ABVX valued at $60.57M. The fund also increased its holdings in COGT by 44.62% and DNTH by 22.16%. Conversely, the manager closed its entire position in CTMX, resulting in a reduction of $8.85M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $130.1M | 11.7% | 3,307,191 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $129.3M | 11.6% | 9,003,418 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $99.0M | 8.91% | 815,176 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $81.4M | 7.32% | 2,048,647 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $76.0M | 6.84% | 3,711,444 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $74.7M | 6.72% | 3,459,913 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $71.3M | 6.41% | 3,705,262 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $68.8M | 6.19% | 1,772,839 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $67.9M | 6.11% | 1,824,031 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $67.3M | 6.06% | 4,018,101 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $62.9M | 5.66% | 727,563 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $60.6M | 5.45% | 713,434 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $42.0M | 3.78% | 1,892,806 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $27.8M | 2.50% | 3,220,368 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $25.9M | 2.33% | 3,554,129 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $16.5M | 1.48% | 1,387,866 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $9.9M | 0.89% | 6,125,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.